| Date Filed | Type | Description |
| 10/04/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,087 shares
@ $3.83, valued at
$4.2k
|
|
| 10/04/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,184 shares
@ $3.83, valued at
$4.5k
|
|
| 10/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,154 shares
@ $3.83, valued at
$4.4k
|
|
| 10/04/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 8,549 shares
@ $3.83, valued at
$32.7k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 91 shares
@ $4.1, valued at
$373.1 |
|
| 07/05/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 151 shares
@ $4.1, valued at
$619.1 |
|
| 07/05/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 157 shares
@ $4.1, valued at
$643.7 |
|
| 07/05/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 981 shares
@ $4.1, valued at
$4k
|
|
| 06/02/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 3,664 shares
@ $3.4563, valued at
$12.7k
|
|
| 06/02/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 2,766 shares
@ $3.4563, valued at
$9.6k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 04/04/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 384 shares
@ $3.08, valued at
$1.2k
|
|
| 04/04/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 480 shares
@ $3.08, valued at
$1.5k
|
|
| 04/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 478 shares
@ $3.08, valued at
$1.5k
|
|
| 04/04/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 2,734 shares
@ $3.08, valued at
$8.4k
|
|
| 03/22/2023 |
4
| LEPORE PATRICK G (Director) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Bought 20,000 shares
@ $2.484, valued at
$49.7k
|
|
| 03/22/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Bought 10,000 shares
@ $2.5, valued at
$25k
|
|
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule BRIDGEWATER, N.J., February 28, 2023 -- VYNE Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on February 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules. According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the last 10 consecutive business days, from February 13, 2023 through February 27, 2023, the closing bid p..." |
|
| 02/10/2023 |
8-K
| Quarterly results |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/12/2023 |
8-K
| Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure,... |
| 01/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,813 shares
@ $0.15, valued at
$272 |
|
| 01/04/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,720 shares
@ $0.15, valued at
$258 |
|
| 01/04/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 354 shares
@ $0.15, valued at
$53.1 |
|
| 01/04/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 10,685 shares
@ $0.15, valued at
$1.6k
|
|
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/18/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
|